Compare LUNR & VRDN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LUNR | VRDN |
|---|---|---|
| Founded | 2013 | 2006 |
| Country | United States | United States |
| Employees | 525 | N/A |
| Industry | Industrial Machinery/Components | Medical Specialities |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.2B | 2.7B |
| IPO Year | N/A | 2014 |
| Metric | LUNR | VRDN |
|---|---|---|
| Price | $23.88 | $14.84 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 9 | 14 |
| Target Price | $20.83 | ★ $36.00 |
| AVG Volume (30 Days) | ★ 14.0M | 3.1M |
| Earning Date | 05-12-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $5,706,000.00 |
| Revenue This Year | $342.04 | $28.34 |
| Revenue Next Year | $16.63 | $235.57 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $6.75 | $11.76 |
| 52 Week High | $25.00 | $34.29 |
| Indicator | LUNR | VRDN |
|---|---|---|
| Relative Strength Index (RSI) | 60.92 | 24.11 |
| Support Level | $15.87 | $14.76 |
| Resistance Level | N/A | $18.57 |
| Average True Range (ATR) | 2.37 | 1.39 |
| MACD | 0.46 | -0.94 |
| Stochastic Oscillator | 89.40 | 10.29 |
Intuitive Machines Inc is a space infrastructure and services company focused on enabling sustained human activity beyond Earth. It designs, builds, integrates, and operates space systems, offering infrastructure-as-a-service across low Earth orbit, geostationary orbit, cislunar space, and deep space. Its capabilities include spacecraft development and space-based network connectivity, serving commercial, civil, and national security customers. The company conducts sales both directly and through an extensive customer and partner network spanning North America, South America, Europe, Asia, and Australia, including rideshare delivery providers, lunar surface mobility providers, payload providers, communication satellite providers, and ground segment providers.
Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. Its product candidate includes Veligrotug (formerly known as VRDN-001) for intravenous (IV) and VRDN-003 for subcutaneous (SC) administration. Veligrotug is a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered for the treatment of thyroid eye disease (TED).